MIS-C and Visceral Leishmaniasis Co-occurence: Has the Clinic of Other Diseases Masked in the Pandemia?
PDF
Cite
Share
Request
Case Report
P: 242-245
September 2022

MIS-C and Visceral Leishmaniasis Co-occurence: Has the Clinic of Other Diseases Masked in the Pandemia?

Turkiye Parazitol Derg 2022;46(3):242-245
1. Sağlık Bilimleri Üniversitesi, Adana Şehir ve Eğitim Araştırma Hastanesi, Çocuk Enfeksiyon Kliniği, Adana, Türkiye
2. Sağlık Bilimleri Üniversitesi, Adana Şehir ve Eğitim Araştırma Hastanesi, Çocuk Hematoloji ve Onkoloji Kliniği, Adana, Türkiye
3. Sağlık Bilimleri Üniversitesi, Adana Şehir ve Eğitim Araştırma Hastanesi, Çocuk Sağlığı ve Hastalıkları Kliniği, Adana, Türkiye
No information available.
No information available
Received Date: 05.10.2021
Accepted Date: 14.04.2022
Publish Date: 12.09.2022
PDF
Cite
Share
Request

ABSTRACT

At the end of 2019, the newly detected severe acute respiratory syndrome-coronavirus (COVID)-2 in China spread rapidly and caused a global epidemic. It has been observed that the virus, which is the cause of COVID-2019 and can cause severe acute respiratory failure, later causes a hyperinflammatory picture and causes a clinical picture similar to Kawasaki disease. Fever, cardiac involvement and rash are the most common findings in this picture, which is called multisystem inflammatory syndrome (MIS-C). Although its pathophysiology is not fully known yet, the most common cause is thought to be post-infection immune dysregulation. Visceral leishmaniasis (VL) is a zoonosis in which Leishmania infantum and rarely Leishmania donovani are the agents and can cause a similar clinical picture. In this text; we discussed a patient who was followed up with a diagnosis of COVID-associated MIS-C, but without an adequate response in his clinic with MIS-C treatment, and was diagnosed with VL with further examinations. To our knowledge, this is the first MIS-C and VL co-occurence in the literature.

Keywords: Child, multisystem inflammatory syndrome, visceral leishmaniasis, SARS-CoV-2

References

1
WHO Coronavirus (COVID-19) Dashboard. Available from: URL: https://covid19.who.inthttps//covid19.who.int/
2
Sirekbasan S, Polat E. A Retrospective Study of Cutaneous and Visceral Leishmaniasis in Istanbul, Turkey. J Infect Dev Ctries 2021; 15: 595-9.
3
Günlük COVID-19 Aşı Tablosu. Erişim adresi: URL: https://covid19.saglik.gov.tr
4
Leidman E, Duca LM, Omura JD, Proia K, Stephens JW, Sauber-Schatz EK. COVID-19 Trends Among Persons Aged 0-24 Years - United States, March 1-December 12, 2020. MMWR Morb Mortal Wkly Rep 2021; 70: 88-94.
5
Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). Available from: URL: https://www.cdc.gov/
6
Liguoro I, Pilotto C, Bonanni M, Ferrari ME, Pusiol A, Nocerino A, et al. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr 2020; 179: 1029-46.
7
World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19: Scientific Brief 2020.
8
Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children (Basel) 2020; 7: 69.
9
Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J 2003; 22: 663-6.
10
Ohga S, Ooshima A, Fukushige J, Ueda K. Histiocytic haemophagocytosis in a patient with Kawasaki disease: changes in the hypercytokinaemic state. Eur J Pediatr 1995; 154: 539-41.
11
Suresh N, Sankar J. Macrophage activation syndrome: a rare complication of incomplete Kawasaki disease. Ann Trop Paediatr 2010; 30: 61-4.
12
Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH‐2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124-31.
13
Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program 2013; 2013: 605-11.
14
Carvalho FHG, Lula JF, Teles LF, Caldeira AP, Carvalho SFG. Hemophagocytic lymphohistiocytosis secondary to visceral leishmaniasis in an endemic area in the north of Minas Gerais, Brazil. Rev Soc Bras Med Trop 2020; 53: e20190491.
15
Arik Yilmaz E, Tanir G, Tuygun N, Taylan Ozkan A. Visceral leishmaniasis in 13 pediatric patients in Turkey: treatment experience. Turkiye Parazitol Derg 2009; 33: 259-62.
2024 ©️ Galenos Publishing House